A股異動丨國藥股份(600511.SH)漲4.6% 數十萬新冠滅活疫苗接種者目前零感染
格隆匯9月11日丨國藥股份(600511.SH)漲4.6%,國藥一致(000028.SZ)則漲逾2%。

國藥集團中國生物負責人昨日就新冠滅活疫苗緊急使用和海外III期臨牀研究情況接受媒體採訪時透露,國藥中國生物研製的兩款新冠滅活疫苗緊急使用,已經接種了數十萬人次,無一例明顯不良反應,無一人感染;其中打完疫苗之後去海外高風險國家和地區的數萬人,截至目前實現了零感染。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.